Inhibition of autophagy with chloroquine potentiates carfilzomib-induced apoptosis in myeloma cells in vitro and in vivo

Cancer Letters

Volumn 382, Issue 1, 2016, Pages 1-10

  Jarauta, Vidal ^a   Jaime, Paula ^a   Gonzalo, Oscar ^a   de Miguel, Diego ^a   Ramírez Labrada, Ariel ^a   Martínez Lostao, Luis ^b   Anel, Alberto ^a   Pardo, Julián ^c   Marzo, Isabel ^a   Naval, Javier ^a  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^c FUNDACIÓN ARAID   (Spain)

Author keywords

Apoptosis; Autophagy; Carfilzomib; Immunogenic cell death; Myeloma

Indexed keywords

BECLIN 1; BIM PROTEIN; BORTEZOMIB; CALRETICULIN; CARFILZOMIB; CASPASE; CHLOROQUINE; CYTOCHROME C; PROTEIN BAX; PROTEIN BCL 2; PROTEIN NOXA; PROTEIN P62; PUMA PROTEIN; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; BECN1 PROTEIN, HUMAN; CALRETICULIN, HUMAN; OLIGOPEPTIDE; PROTEASOME INHIBITOR; SEQUESTOSOME 1; SQSTM1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CANCER COMBINATION CHEMOTHERAPY; CELL DEATH; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR INTERACTION; MOUSE; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; UPREGULATION; ANIMAL; DOSE RESPONSE; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; ENZYMOLOGY; METABOLISM; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; BECLIN-1; CALRETICULIN; CELL LINE, TUMOR; CHLOROQUINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; MICE, NUDE; MULTIPLE MYELOMA; OLIGOPEPTIDES; PROTEASOME INHIBITORS; SEQUESTOSOME-1 PROTEIN; SIGNAL TRANSDUCTION; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84984656472     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.08.019     Document Type: Article

References (33)

1. [1] Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016. CA Cancer J. Clin 66 (2016), 7–30.
2. [2] Avet-Loiseau, H., Ultra high-risk myeloma. Hematology Am. Soc. Hematol. Educ. Program, 2010, 489–493.
3. [3] Lonial, S., Boise, L.H., Kaufman, J., How I treat high-risk myeloma. Blood 126 (2015), 1536–1543.
4. [4] Richardson, P.G., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., et al. I. Assessment of proteasome inhibition for extending remissions, bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med 352 (2005), 2487–2498.
5. [5] Scheid, C., ENDEAVOR to change treatment for multiple myeloma?. Lancet Oncol 17 (2016), 2–3.
6. [6] Parlati, F., Lee, S.J., Aujay, M., Suzuki, E., Levitsky, K., Lorens, J.B., et al. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 114 (2009), 3439–3447.
7. [7] Awan, F.T., Flynn, J.M., Jones, J.A., Andritsos, L.A., Maddocks, K.J., Sass, E.J., et al. Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma. Leuk. Lymphoma 56 (2015), 2834–2840.
8. [8] Mehta, A., Zhang, L., Boufraqech, M., Zhang, Y., Patel, D., Shen, M., et al. Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer. Endocr. Relat. Cancer 22 (2015), 319–329.
9. [9] Okamoto, K., Zaanan, A., Kawakami, H., Huang, S., Sinicrope, F.A., Reversal of mutant KRAS-mediated apoptosis resistance by concurrent Noxa/Bik induction and Bcl-2/Bcl-xL antagonism in colon cancer cells. Mol. Cancer Res 13 (2015), 659–669.
10. [10] Zhang, L., Pham, L.V., Newberry, K.J., Ou, Z., Liang, R., Qian, J., et al. In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome. Mol. Cancer Ther 12 (2013), 2494–2504.
11. [11] Kuhn, D.J., Chen, Q., Voorhees, P.M., Strader, J.S., Shenk, K.D., Sun, C.M., et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 110 (2007), 3281–3290.
12. [12] Korde, N., Roschewski, M., Zingone, A., Kwok, M., Manasanch, E.E., Bhutani, M., et al. Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol 1 (2015), 746–754.
13. [13] MacFarlane, M., Ahmad, M., Srinivasula, S.M., Fernandes-Alnemri, T., Cohen, G.M., Alnemri, E.S., Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J. Biol. Chem 272 (1997), 25417–25420.
14. [14] Gomez-Benito, M., Balsas, P., Carvajal-Vergara, X., Pandiella, A., Anel, A., Marzo, I., et al. Mechanism of apoptosis induced by IFN-alpha in human myeloma cells: role of Jak1 and Bim and potentiation by rapamycin. Cell. Signal 19 (2007), 844–854.
15. [15] Balsas, P., Lopez-Royuela, N., Galan-Malo, P., Anel, A., Marzo, I., Naval, J., Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis. Biochem. Pharmacol 77 (2009), 804–812.
16. [16] Lopez-Royuela, N., Balsas, P., Galan-Malo, P., Anel, A., Marzo, I., Naval, J., Bim is the key mediator of glucocorticoid-induced apoptosis and of its potentiation by rapamycin in human myeloma cells. Biochim. Biophys. Acta 1803 (2010), 311–322.
17. [17] Roecklein, B.A., Torok-Storb, B., Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6/E7 genes. Blood 85 (1995), 997–1005.
18. [18] Lopez-Royuela, N., Perez-Galan, P., Galan-Malo, P., Yuste, V.J., Anel, A., Susin, S.A., et al. Different contribution of BH3-only proteins and caspases to doxorubicin-induced apoptosis in p53-deficient leukemia cells. Biochem. Pharmacol 79 (2010), 1746–1758.
19. [19] Vela, L., Gonzalo, O., Naval, J., Marzo, I., Direct interaction of Bax and Bak proteins with Bcl-2 homology domain 3 (BH3)-only proteins in living cells revealed by fluorescence complementation. J. Biol. Chem 288 (2013), 4935–4946.
20. [20] Gomez-Benito, M., Marzo, I., Anel, A., Naval, J., Farnesyltransferase inhibitor BMS-214662 induces apoptosis in myeloma cells through PUMA up-regulation, Bax and Bak activation, and Mcl-1 elimination. Mol. Pharmacol 67 (2005), 1991–1998.
21. [21] Pardo, J., Galvez, E.M., Koskinen, A., Simon, M.M., Lobigs, M., Regner, M., et al. Caspase-dependent inhibition of mousepox replication by gzmB. PLoS ONE, 4, 2009, e7512.
22. [22] Li, H., Wang, P., Sun, Q., Ding, W.X., Yin, X.M., Sobol, R.W., et al. Following cytochrome c release, autophagy is inhibited during chemotherapy-induced apoptosis by caspase 8-mediated cleavage of Beclin 1. Cancer Res 71 (2011), 3625–3634.
23. [23] Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G.M., Apetoh, L., Perfettini, J.L., et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med 13 (2007), 54–61.
24. [24] Garderet, L., Iacobelli, S., Moreau, P., Dib, M., Lafon, I., Niederwieser, D., et al. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J. Clin. Oncol 30 (2012), 2475–2482.
25. [25] Arastu-Kapur, S., Anderl, J.L., Kraus, M., Parlati, F., Shenk, K.D., Lee, S.J., et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin. Cancer Res 17 (2011), 2734–2743.
26. [26] Dimopoulos, M.A., Moreau, P., Palumbo, A., Joshua, D., Pour, L., Hajek, R., et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 17 (2016), 27–38.
27. [27] Han, B., Yao, W., Oh, Y.T., Tong, J.S., Li, S., Deng, J., et al. The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5. Oncotarget 6 (2015), 17532–17542.
28. [28] Matsuzawa, Y., Oshima, S., Nibe, Y., Kobayashi, M., Maeyashiki, C., Nemoto, Y., et al. RIPK3 regulates p62-LC3 complex formation via the caspase-8-dependent cleavage of p62. Biochem. Biophys. Res. Commun 456 (2015), 298–304.
29. [29] Riz, I., Hawley, T.S., Hawley, R.G., KLF4-SQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models. Oncotarget 6 (2015), 14814–14831.
30. [30] Hoang, B., Benavides, A., Shi, Y., Frost, P., Lichtenstein, A., Effect of autophagy on multiple myeloma cell viability. Mol. Cancer Ther 8 (2009), 1974–1984.
31. [31] Vogl, D.T., Stadtmauer, E.A., Tan, K.S., Heitjan, D.F., Davis, L.E., Pontiggia, L., et al. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. Autophagy 10 (2014), 1380–1390.
32. [32] Kroemer, G., Galluzzi, L., Kepp, O., Zitvogel, L., Immunogenic cell death in cancer therapy. Annu. Rev. Immunol 31 (2013), 51–72.
33. [33] Cirone, M., Di Renzo, L., Lotti, L.V., Conte, V., Trivedi, P., Santarelli, R., et al. Primary effusion lymphoma cell death induced by bortezomib and AG 490 activates dendritic cells through CD91. PLoS ONE, 7, 2012, e31732.